Vericel Corp is a US-based pharmaceutical company with a medium risk ESG score of 25.5. Specializing in therapies for sports medicine and severe burn care, Vericel Corp offers two cell therapy products - MACI and Epicel. The company focuses on research, product development, manufacture, and distribution of patient-specific cellular therapies.